Tacrolimus (Advagraf®) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

All Wales Medicines Strategy Group (AWMSG)

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
All Wales Medicines Strategy Group (AWMSG). Tacrolimus (Advagraf®) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1109. 2009

Authors' conclusions
Tacrolimus prolonged-release (Advagraf®) is not recommended for use within NHS Wales for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients. The cost effectiveness data presented was insufficient for AWMSG to recommend its use. Healthcare professionals should not stop prescribing Advagraf® for patients who are already taking it at the time of issue of this advice.

Final publication URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Graft Rejection; Kidney Transplantation; Liver Transplantations; Tacrolimus

Language Published
English

Country of organisation
Wales

English summary
An English language summary is available.

Address for correspondence
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX Email: AWTTC@wales.nhs.uk

AccessionNumber
32012000410

Date abstract record published
08/08/2012